Literature DB >> 22721988

Diagnosis and therapy of tuberculous meningitis in children.

Nicola Principi1, Susanna Esposito.   

Abstract

Children are among the subjects most frequently affected by tuberculous meningitis (TBM) due to their relative inability to contain primary Mycobacterium tuberculosis infection in the lung. TBM is a devastating disease with about 30% mortality among the most severe cases; moreover, 50% of survivors have neurological sequelae despite an apparently adequate administration of antibiotics. Early diagnosis and prompt treatment are crucial for reducing the risk of a poor outcome. However, especially in children, the best and most rapid way to confirm the diagnosis is controversial; the optimal choice, dose, and treatment duration of anti-tuberculosis drugs are not precisely defined, and the actual importance of adjunctive therapies with steroids and neurosurgery has not been adequately demonstrated. This review is an effort to discuss present knowledge of the diagnosis and treatment of pediatric TBM in order to offer the best solution to address this dramatic disease. In conclusion, we stress that new studies in children are urgently needed because data in the early years of life are more debatable than those collected in adults. In the meantime, when treating a child with suspected TBM, the most aggressive attitude to diagnosis and therapy is necessary, because TBM is a devastating disease.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22721988     DOI: 10.1016/j.tube.2012.05.011

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  9 in total

1.  γ-herpesvirus latency attenuates Mycobacterium tuberculosis infection in mice.

Authors:  Halli E Miller; Kaitlin E Johnson; Vera L Tarakanova; Richard T Robinson
Journal:  Tuberculosis (Edinb)       Date:  2019-04-30       Impact factor: 3.131

Review 2.  Recommendations for the diagnosis of pediatric tuberculosis.

Authors:  E Chiappini; A Lo Vecchio; S Garazzino; G L Marseglia; F Bernardi; E Castagnola; P Tomà; D Cirillo; C Russo; C Gabiano; D Ciofi; G Losurdo; M Bocchino; E Tortoli; M Tadolini; A Villani; A Guarino; S Esposito
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-01       Impact factor: 3.267

3.  Novel vaccine strategies against tuberculosis: a road less travelled.

Authors:  Supriya Pokkali; Sanjay Jain
Journal:  Expert Rev Vaccines       Date:  2013-12       Impact factor: 5.217

Review 4.  Six months therapy for tuberculous meningitis.

Authors:  Sophie Jullien; Hannah Ryan; Manish Modi; Rohit Bhatia
Journal:  Cochrane Database Syst Rev       Date:  2016-09-01

5.  A hypothetical astrocyte-microglia lactate shuttle derived from a 1H NMR metabolomics analysis of cerebrospinal fluid from a cohort of South African children with tuberculous meningitis.

Authors:  Shayne Mason; A Marceline van Furth; Lodewyk J Mienie; Udo F H Engelke; Ron A Wevers; Regan Solomons; Carolus J Reinecke
Journal:  Metabolomics       Date:  2014-10-11       Impact factor: 4.290

Review 6.  Recommendations Concerning the First-Line Treatment of Children with Tuberculosis.

Authors:  Nicola Principi; Luisa Galli; Laura Lancella; Marina Tadolini; Giovanni Battista Migliori; Alberto Villani; Susanna Esposito
Journal:  Paediatr Drugs       Date:  2016-02       Impact factor: 3.930

Review 7.  Tuberculosis in children.

Authors:  Susanna Esposito; Claudia Tagliabue; Samantha Bosis
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-11-04       Impact factor: 2.576

8.  Modeling tuberculous meningitis in zebrafish using Mycobacterium marinum.

Authors:  Lisanne M van Leeuwen; Martijn van der Kuip; Sameh A Youssef; Alain de Bruin; Wilbert Bitter; A Marceline van Furth; Astrid M van der Sar
Journal:  Dis Model Mech       Date:  2014-07-04       Impact factor: 5.758

Review 9.  Tuberculous meningitis in children: Clinical management & outcome.

Authors:  Bella Devaleenal Daniel; G Angeline Grace; Mohan Natrajan
Journal:  Indian J Med Res       Date:  2019-08       Impact factor: 2.375

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.